| Patient | Julius Caesar |
|---|---|
| Date of birth | 1972-07-12 |
| Identifiers | MRN HR-AC001-SYN; SSN (made up) 000-01-6022 |
| Document date | 2026-11-01 |
| Author | Lucius Fairbanks-Okonkwo, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Urgent visit after a witnessed collapse with jerking and confusion, the third spell in eighteen months: history, examination, ECG, tests, cardiac monitor, seizure safety, and neurology referral. Concerns: Six days ago he collapsed at a long outdoor ceremony after a strange rising feeling, with jerking of both arms, a bitten tongue, and twenty minutes of confusion; it is his third spell in eighteen months, and he wants to know why he collapses and whether it will happen again in public; He wants to keep working, travelling, speaking, and riding; He is frustrated at being told not to drive. [S]
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Lisinopril 10 mg oral tablet, one tablet by mouth daily | One tablet by mouth each morning | Oral route | 2026-08-04 | active | S |
| Levetiracetam 500 mg oral tablet, one tablet by mouth twice daily | 500 mg twice daily, morning and evening | Oral route | 2026-08-18 | active | S |
| Atorvastatin 80 mg oral tablet, one tablet by mouth at bedtime | One tablet by mouth at bedtime | Oral route | 2026-08-18 | active | S |
| Aspirin 81 mg delayed-release tablet, one tablet by mouth daily | One tablet by mouth daily with food | Oral route | 2026-08-18 | active | S |
| Acetaminophen 500 mg oral tablet, one or two tablets by mouth every 6 hours as needed for fever or sore throat (no more than 3 g a day) | One or two tablets every 6 hours as needed, at most 3 g a day, for up to a week | Oral route | 2026-09-08 to 2026-09-14 | completed | S |
| Amlodipine 5 mg oral tablet, one tablet by mouth daily | One tablet by mouth each morning | Oral route | 2026-09-15 | active | S |
| Procedure | Dates | Status | Evidence |
|---|---|---|---|
| 12-lead ECG: sinus rhythm at 70 per minute, PR 168 ms, QRS 92 ms, QTc 412 ms, voltage criteria for left ventricular hypertrophy; no pre-excitation, Brugada pattern, or heart block | 2026-08-04 to 2026-08-04 | completed | S |
| 14-day ambulatory ECG patch, fitted the day after the first visit: sinus rhythm throughout, no atrial fibrillation or flutter, no pause longer than 2 seconds, no high-grade block; one patient-triggered event (light-headed on standing) in sinus rhythm | 2026-08-05 to 2026-08-18 | completed | S |
| Routine EEG with sleep: intermittent left temporal sharp waves in drowsiness and light sleep; normal background; no seizure recorded | 2026-08-11 to 2026-08-11 | completed | S |
| MRI of the brain with diffusion-weighted, susceptibility-weighted, and epilepsy-protocol sequences: no acute infarct; a chronic 1.5 cm cortical and subcortical infarct with gliosis in the left posterior temporal lobe; moderate periventricular and deep white matter hyperintensities (Fazekas grade 2); no microbleeds, mass, vascular malformation, cyst, or calcified lesion; hippocampi normal | 2026-08-12 to 2026-08-12 | completed | S |
| CT angiography of the head and neck: calcified plaque at the left carotid bifurcation with less than 30 percent stenosis; no other extracranial or intracranial stenosis, dissection, aneurysm, or arteriovenous malformation | 2026-08-12 to 2026-08-12 | completed | S |
| Transthoracic echocardiogram with agitated saline: ejection fraction 60 percent, mild concentric left ventricular hypertrophy, normal left atrial size, no thrombus or valve disease; no shunt | 2026-08-13 to 2026-08-13 | completed | S |
| Second ambulatory ECG monitor for four more weeks (more than 40 days of monitoring in all): sinus rhythm throughout; no atrial fibrillation or flutter; rare isolated ectopic beats | 2026-08-18 to 2026-09-14 | completed | S |
| Home sleep apnea test: apnea-hypopnea index 4 per hour, oxygen saturation nadir 91 percent; no sleep apnea | 2026-09-10 to 2026-09-10 | completed | S |
| Advance care planning conversation, about 20 minutes | 2026-10-06 to 2026-10-06 | completed | S |
| Date | Vaccine | Status | Evidence |
|---|---|---|---|
| 2019-04-10 | Tetanus, diphtheria, and pertussis (Tdap) booster | completed | S |
| 2026-10-06 | Influenza vaccine, 2026-2027 season | completed | S |
| 2026-10-06 | Recombinant zoster vaccine, dose 1 of 2 | completed | S |
| 2026-10-06 | Pneumococcal conjugate vaccine (PCV20), single dose | completed | S |
Historical biography with true dates. These events are not part of the synthetic care timeline.
| Historical date | History | Evidence |
|---|---|---|
| about 82 to 81 BC | A severe quartan fever (a fever every fourth day) while in hiding as a young man | D (CLM-0004) |
| date not recorded | Plutarch: 'distemper in the head' and 'epileptic fits', the first at Corduba in Spain; the date is not recorded | D (CLM-0005) |
| his last years; no dates recorded | Suetonius: sudden fainting fits and nightmares towards the end of his life, and two attacks of the 'falling sickness' (comitialis morbus) on campaign | D (CLM-0006) |
| 6 April 46 BC in the old Roman calendar (about 7 February 46 BC, Julian) | By one account in Plutarch, his 'usual sickness' seized him at the battle of Thapsus and he was carried to a tower | D (CLM-0007) |
| retrospective interpretation | The nature of the attacks is disputed: epilepsy, transient ischemic attacks, and other causes have all been proposed | R (CLM-0013, CLM-0014, CLM-0015) |
| Relative | Condition | Age at death | Evidence |
|---|---|---|---|
| father | Died suddenly in the morning, without apparent cause, while putting on his shoes, when his son was fifteen; cause not recorded in the cited source | D (CLM-0002, CLM-0003) | |
| natural daughter | Died in childbirth as a young woman | D (CLM-0010) |
| Concern | Status | Evidence |
|---|---|---|
| Six days ago he collapsed at a long outdoor ceremony after a strange rising feeling, with jerking of both arms, a bitten tongue, and twenty minutes of confusion; it is his third spell in eighteen months, and he wants to know why he collapses and whether it will happen again in public | active | S |
| He wants to keep working, travelling, speaking, and riding | active | S |
| He is frustrated at being told not to drive | active | S |
Most recent measures: Hemoglobin [Mass/volume] in Blood 14.8 on 2026-08-04; Leukocytes [#/volume] in Blood by Automated count 6.9 on 2026-08-04; Platelets [#/volume] in Blood by Automated count 232 on 2026-08-04; Sodium [Moles/volume] in Serum or Plasma 140 on 2026-08-18; Potassium [Moles/volume] in Serum or Plasma 4.5 on 2026-08-18; Creatinine [Mass/volume] in Serum or Plasma 1.02 on 2026-08-18; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 86 on 2026-08-18; Glucose [Mass/volume] in Serum or Plasma 96 on 2026-08-04; Calcium [Mass/volume] in Serum or Plasma 9.4 on 2026-08-04; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 34 on 2026-10-27; Hemoglobin A1c/Hemoglobin.total in Blood 5.6 on 2026-08-04; Thyrotropin [Units/volume] in Serum or Plasma 1.8 on 2026-08-04; Cholesterol [Mass/volume] in Serum or Plasma 136 on 2026-10-27; Cholesterol in HDL [Mass/volume] in Serum or Plasma 46 on 2026-10-27; Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 68 on 2026-10-27; Triglyceride [Mass/volume] in Serum or Plasma 110 on 2026-10-27; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 3 on 2026-10-27; Total score [AUDIT-C] 1 on 2026-10-06; Total score [MoCA] 28 on 2026-09-15; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 0 on 2026-10-06 [S]
Strengths and supports: engagement in care [S]
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Recurrent transient episodes of collapse: six days ago a witnessed collapse with stiffening and jerking of both arms for about a minute, a bitten tongue, and about twenty minutes of confusion, after a rising strange feeling and dizziness; two briefer spells of staring and unresponsiveness in the past eighteen months; cause not yet known (seizure, convulsive syncope, or transient ischemic attack) | resolved | confirmed | R56.9 | S — Synthetic presenting problem anchored to the documented accounts of falling attacks and fainting fits; it resolves when the cause is found. |
| Hypertension, stage 2: 152/94 and 148/92 mmHg today; told of high blood pressure about three years ago and never treated | active | confirmed | I10 | S — Synthetic vascular risk factor; no blood pressure from his lifetime is known. |
| Hyperlipidemia: LDL 158 mg/dL, triglycerides 170 mg/dL, HDL 44 mg/dL | active | confirmed | E78.5 | S — Synthetic vascular risk factor; no lipid value from his lifetime is known. |
| Focal epilepsy with a structural vascular cause: focal impaired-awareness seizures with automatisms, one evolving to a bilateral tonic-clonic seizure, arising from a chronic left temporal cortical infarct, with left temporal sharp waves on EEG | active | confirmed | G40.209 | S — Synthetic modern diagnosis anchored to the documented falling attacks; the ILAE 2017 seizure types and a structural cause are chosen for teaching and make no claim about what he had. |
| Chronic left posterior temporal cortical infarct, not recognized before the seizures, with moderate small-vessel white matter disease and a non-stenotic left carotid plaque; no residual deficit | active | confirmed | I69.398 | S — Synthetic modern finding anchored to the retrospective cerebrovascular hypothesis; it makes no claim about his real brain. |
| Acute viral upper respiratory infection with low-grade fever and poor sleep, three weeks after starting levetiracetam; rapid COVID-19 and influenza tests negative; resolved | resolved | confirmed | J06.9 | S — Synthetic intercurrent illness, chosen to teach cold-remedy choices with hypertension, aspirin, and an antiseizure medicine, and sleep loss as a seizure trigger; it echoes no documented illness. |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-08-04 | Hemoglobin [Mass/volume] in Blood | 14.8 | g/dL | 13.2-16.6 g/dL | Normal | S |
| 2026-08-04 | Leukocytes [#/volume] in Blood by Automated count | 6.9 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-08-04 | Platelets [#/volume] in Blood by Automated count | 232 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-08-04 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-08-04 | Potassium [Moles/volume] in Serum or Plasma | 4.2 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-08-04 | Creatinine [Mass/volume] in Serum or Plasma | 0.98 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-08-04 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 91 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-08-04 | Glucose [Mass/volume] in Serum or Plasma | 96 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-08-04 | Calcium [Mass/volume] in Serum or Plasma | 9.4 | mg/dL | 8.6-10.3 mg/dL | Normal | S |
| 2026-08-04 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 28 | U/L | 7-56 U/L | Normal | S |
| 2026-08-04 | Hemoglobin A1c/Hemoglobin.total in Blood | 5.6 | % | <=5.6% | Normal | S |
| 2026-08-04 | Thyrotropin [Units/volume] in Serum or Plasma | 1.8 | m[IU]/L | 0.4-4.5 mIU/L | Normal | S |
| 2026-08-04 | Cholesterol [Mass/volume] in Serum or Plasma | 236 | mg/dL | <=200 mg/dL | High | S |
| 2026-08-04 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 44 | mg/dL | >=40 mg/dL | Normal | S |
| 2026-08-04 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 158 | mg/dL | <=129 mg/dL | High | S |
| 2026-08-04 | Triglyceride [Mass/volume] in Serum or Plasma | 170 | mg/dL | <=149 mg/dL | High | S |
| 2026-08-04 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 3 | {score} | S | ||
| 2026-08-04 | Total score [AUDIT-C] | 1 | {score} | S | ||
| 2026-08-18 | Sodium [Moles/volume] in Serum or Plasma | 140 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-08-18 | Potassium [Moles/volume] in Serum or Plasma | 4.5 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-08-18 | Creatinine [Mass/volume] in Serum or Plasma | 1.02 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-08-18 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 86 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-09-15 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 4 | {score} | S | ||
| 2026-09-15 | Total score [MoCA] | 28 | {score} | S | ||
| 2026-10-27 | Cholesterol [Mass/volume] in Serum or Plasma | 136 | mg/dL | <=200 mg/dL | Normal | S |
| 2026-10-27 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 46 | mg/dL | >=40 mg/dL | Normal | S |
| 2026-10-27 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 68 | mg/dL | <=129 mg/dL | Normal | S |
| 2026-10-27 | Triglyceride [Mass/volume] in Serum or Plasma | 110 | mg/dL | <=149 mg/dL | Normal | S |
| 2026-10-27 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 34 | U/L | 7-56 U/L | Normal | S |
| 2026-10-27 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 3 | {score} | S | ||
| 2026-10-06 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | S | ||
| 2026-10-06 | Total score [AUDIT-C] | 1 | {score} | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-08-04 | Body height | 182 | cm | S |
| 2026-08-04 | Body weight | 76 | kg | S |
| 2026-08-04 | Body mass index (BMI) [Ratio] | 22.9 | kg/m2 | S |
| 2026-08-04 | Systolic blood pressure | 152 | mm[Hg] | S |
| 2026-08-04 | Diastolic blood pressure | 94 | mm[Hg] | S |
| 2026-08-04 | Heart rate | 70 | /min | S |
| 2026-08-04 | Respiratory rate | 14 | /min | S |
| 2026-08-04 | Body temperature | 36.7 | Cel | S |
| 2026-08-04 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-08-18 | Body height | 182 | cm | S |
| 2026-08-18 | Body weight | 75.8 | kg | S |
| 2026-08-18 | Body mass index (BMI) [Ratio] | 22.9 | kg/m2 | S |
| 2026-08-18 | Systolic blood pressure | 140 | mm[Hg] | S |
| 2026-08-18 | Diastolic blood pressure | 88 | mm[Hg] | S |
| 2026-08-18 | Heart rate | 68 | /min | S |
| 2026-08-18 | Respiratory rate | 14 | /min | S |
| 2026-08-18 | Body temperature | 36.6 | Cel | S |
| 2026-08-18 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-09-08 | Body height | 182 | cm | S |
| 2026-09-08 | Body weight | 75.4 | kg | S |
| 2026-09-08 | Body mass index (BMI) [Ratio] | 22.8 | kg/m2 | S |
| 2026-09-08 | Systolic blood pressure | 136 | mm[Hg] | S |
| 2026-09-08 | Diastolic blood pressure | 86 | mm[Hg] | S |
| 2026-09-08 | Heart rate | 84 | /min | S |
| 2026-09-08 | Respiratory rate | 16 | /min | S |
| 2026-09-08 | Body temperature | 37.8 | Cel | S |
| 2026-09-08 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| 2026-09-15 | Body height | 182 | cm | S |
| 2026-09-15 | Body weight | 75.6 | kg | S |
| 2026-09-15 | Body mass index (BMI) [Ratio] | 22.8 | kg/m2 | S |
| 2026-09-15 | Systolic blood pressure | 136 | mm[Hg] | S |
| 2026-09-15 | Diastolic blood pressure | 84 | mm[Hg] | S |
| 2026-09-15 | Heart rate | 68 | /min | S |
| 2026-09-15 | Respiratory rate | 14 | /min | S |
| 2026-09-15 | Body temperature | 36.6 | Cel | S |
| 2026-09-15 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-10-06 | Body height | 182 | cm | S |
| 2026-10-06 | Body weight | 75.2 | kg | S |
| 2026-10-06 | Body mass index (BMI) [Ratio] | 22.7 | kg/m2 | S |
| 2026-10-06 | Systolic blood pressure | 128 | mm[Hg] | S |
| 2026-10-06 | Diastolic blood pressure | 80 | mm[Hg] | S |
| 2026-10-06 | Heart rate | 66 | /min | S |
| 2026-10-06 | Respiratory rate | 14 | /min | S |
| 2026-10-06 | Body temperature | 36.6 | Cel | S |
| 2026-10-06 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-10-27 | Body height | 182 | cm | S |
| 2026-10-27 | Body weight | 75 | kg | S |
| 2026-10-27 | Body mass index (BMI) [Ratio] | 22.6 | kg/m2 | S |
| 2026-10-27 | Systolic blood pressure | 124 | mm[Hg] | S |
| 2026-10-27 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-10-27 | Heart rate | 66 | /min | S |
| 2026-10-27 | Respiratory rate | 14 | /min | S |
| 2026-10-27 | Body temperature | 36.6 | Cel | S |
| 2026-10-27 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Purpose | Status | Provenance |
|---|---|---|---|
| 2026-08-04 | Urgent visit after a witnessed collapse with jerking and confusion, the third spell in eighteen months: history, examination, ECG, tests, cardiac monitor, seizure safety, and neurology referral | finished | S |
| 2026-08-18 | Two-week follow-up with the neurology consultation: EEG, MRI, vascular imaging, echocardiogram, and monitor reviewed; diagnosis made and treatment started | finished | S |
| 2026-09-08 | Same-day sick visit for a cold with low fever | finished | S |
| 2026-09-15 | Four-week review of levetiracetam, blood pressure, the second rhythm monitor, mood, and cognition | finished | S |
| 2026-10-06 | Adult preventive visit | finished | S |
| 2026-10-27 | Ten-week review: seizure control, lipids on atorvastatin, blood pressure, and driving and safety | finished | S |
| Intervention | Status | Guideline | Provenance |
|---|---|---|---|
| Work-up of transient loss of consciousness: witness account, orthostatic vital signs, 12-lead ECG today, a 14-day ambulatory ECG patch from tomorrow, blood count, electrolytes, calcium, glucose, kidney and liver tests, HbA1c, lipids, and TSH; EEG and MRI of the brain with diffusion-weighted and epilepsy-protocol sequences; CT angiography of the head and neck; transthoracic echocardiogram | completed | GL-AAN-FIRSTSZ-2015, GL-ACC-SYNC-2017, GL-AHA-SSP-2021 | S |
| Neurology consultation: is this epilepsy, syncope, or transient ischemic attack; review of the EEG, MRI, and vascular imaging; whether to start an antiseizure medicine and which; stroke prevention; and driving | completed | GL-AAN-FIRSTSZ-2015, GL-ILAE-SZ-2017 | S |
| Seizure safety from today: no driving until a seizure-free period set by state law and his neurologist; showers rather than baths; no swimming or riding alone; no climbing to heights; regular sleep of at least seven hours; a written seizure action plan for his staff, including when to call emergency services | completed | GL-AAN-FIRSTSZ-2015 | S |
| Blood pressure: lisinopril 10 mg daily from today; home blood pressure log twice daily; potassium and creatinine in two weeks; target below 130/80 mmHg | completed | GL-AHA-HTN-2025, GL-CMID-2026 | S |
| Antiseizure medicine: levetiracetam 500 mg twice daily, with teaching about irritability, low mood, and drowsiness; a seizure diary; no missed doses | completed | GL-AAN-NEWASM-2018, GL-AAN-FIRSTSZ-2015 | S |
| Secondary stroke prevention for the cortical infarct: aspirin 81 mg daily, atorvastatin 80 mg at bedtime with a lipid panel at 4 to 12 weeks (LDL target below 70 mg/dL), blood pressure below 130/80 mmHg with a second drug if needed, a home sleep apnea test, and a further four weeks of ambulatory rhythm monitoring (more than 30 days in all) for occult atrial fibrillation | completed | GL-AHA-SSP-2021, GL-AHA-SILENT-2017, GL-CMID-2026 | S |
| Lifestyle: Mediterranean-style diet with sodium below 2.3 g a day; aerobic activity at least 150 minutes a week; alcohol kept at his present low level; no tobacco | completed | GL-AHA-SSP-2021, GL-CMID-2026 | S |
| Mood and cognition after the diagnosis: PHQ-9 four weeks after starting levetiracetam and then periodically; MoCA in the first months after the infarct was found | completed | GL-CMID-2026, GL-AHA-SSP-2021 | S |
| Adult prevention plan: influenza, pneumococcal, and recombinant zoster vaccines; hepatitis C, hepatitis B, and HIV screening; colonoscopy for colorectal cancer screening; eye examination; PSA discussion at 55 | completed | GL-PREV-2026, GL-USPSTF-AB, GL-CDC-ADULT-2026, GL-USPSTF-CRC-2021 | S |
| Goal | Target | Status | Outcome | Provenance |
|---|---|---|---|---|
| Cause of the spells established and explained to him by the neurology visit | 2026-08-18 | completed | Focal epilepsy with a structural vascular cause, from a chronic left temporal cortical infarct; syncope and transient ischemic attack judged unlikely | S |
| No seizures on levetiracetam through the ten-week review | 2026-10-27 | completed | No seizure or spell since levetiracetam was started ten weeks ago | S |
| Office blood pressure below 130/80 mmHg | 2026-10-27 | completed | 124/76 mmHg on lisinopril 10 mg and amlodipine 5 mg | S |
| LDL cholesterol below 70 mg/dL on a high-intensity statin | 2026-10-27 | completed | LDL 68 mg/dL after ten weeks of atorvastatin 80 mg | S |
| No driving, swimming alone, or riding alone while the seizure-free period is counted, with a written seizure action plan for his staff | 2026-10-27 | active | Not driving; a driver and a riding companion arranged; seizure action plan given to his staff | S |